{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17"],"submitter":["Rios Rodriguez V"],"pubmed_abstract":["<h4>Background</h4>Early treatment initiation is one of the strongest predictors of good treatment response in axial spondyloarthritis (axSpA). Recently, the Assessment in SpondyloArthritis International Society (ASAS) defined early axSpA as a diagnosis of axSpA with a duration of axial symptoms equal to or less than 2 years. Tofacitinib is a Janus kinase (JAK) inhibitor for the treatment of ankylosing spondylitis.<h4>Objectives</h4>Compare the efficacy and safety of tofacitinib versus placebo (both on non-steroidal anti-inflammatory drug (NSAID) background) in patients with active early axSpA and inadequate response to at least one NSAID.<h4>Design</h4>This is a phase IV, randomized, double-blind, placebo-controlled, multicenter clinical trial.<h4>Methods and analysis</h4>The study will r"],"journal":["Therapeutic advances in musculoskeletal disease"],"pagination":["1759720X251324429"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11898075"],"repository":["biostudies-literature"],"pubmed_title":["Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE."],"pmcid":["PMC11898075"],"pubmed_authors":["Sanchez-Riera L","Proft F","Torgutalp M","Rios Rodriguez V","Binder E","Zhao Y","Hoppner C","Mundayat R","Diehl A","Haibel H","Yndestad A","Rademacher J","Vranic I","Poddubnyy D"],"additional_accession":[]},"is_claimable":false,"name":"Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE.","description":"<h4>Background</h4>Early treatment initiation is one of the strongest predictors of good treatment response in axial spondyloarthritis (axSpA). Recently, the Assessment in SpondyloArthritis International Society (ASAS) defined early axSpA as a diagnosis of axSpA with a duration of axial symptoms equal to or less than 2 years. Tofacitinib is a Janus kinase (JAK) inhibitor for the treatment of ankylosing spondylitis.<h4>Objectives</h4>Compare the efficacy and safety of tofacitinib versus placebo (both on non-steroidal anti-inflammatory drug (NSAID) background) in patients with active early axSpA and inadequate response to at least one NSAID.<h4>Design</h4>This is a phase IV, randomized, double-blind, placebo-controlled, multicenter clinical trial.<h4>Methods and analysis</h4>The study will r","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-02T21:04:58.749Z","creation":"2025-04-04T01:29:04.766Z"},"accession":"S-EPMC11898075","cross_references":{"pubmed":["40078463"],"doi":["10.1177/1759720X251324429"]}}